

RECEIVED

NOV 07 2008

PTO/SB/68 (08-06)

Approved for use through 3/31/2007. OMB 0651-0031

File Information Unit

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

REQUEST FOR ACCESS TO AN ABANDONED APPLICATION UNDER 37 CFR 1.14

Bring completed form to:
File Information Unit, Room 2E04
2900 Crystal Drive
Arlington, VA 22202-3514

Telephone: (703) 308-2733

In re Application of

Kucherlapati et al

Application Number

08/112848

Filed

8/27/93

Paper No. 36

I hereby request access under 37 CFR 1.14(a)(1)(iv) to the application file record of the above-identified ABANDONED application, which is not within the file jacket of a pending Continued Prosecution Application (CPA) (37 CFR 1.53(d)) and which is identified in, or to which a benefit is claimed, in the following document (as shown in the attachment):

United States Patent Application Publication No. _____, page, _____, line _____

United States Patent Number 6713610, column 1, line, 1 or

WIPO Pub. No. _____, page _____, line _____

Related Information About Access to Applications Maintained in the Image File Wrapper System (IFW) and Access to Pending Applications in General

A member of the public, acting without a power to inspect, cannot order applications maintained in the IFW system through the FIU. If the member of the public is entitled to a copy of the application file, then the file is made available through the Public Patent Application Information Retrieval system (Public PAIR) on the USPTO internet web site (www.uspto.gov). Terminals that allow access to Public PAIR are available in the Public Search Room. The member of the public may also be entitled to obtain a copy of all or part of the application file upon payment of the appropriate fee. Such copies must be purchased through the Office of Public Records upon payment of the appropriate fee (37 CFR 1.19(b)).

For published applications that are still pending, a member of the public may obtain a copy of:

the file contents; the pending application as originally filed; or any document in the file of the pending application.

For unpublished applications that are still pending:

- (1) If the benefit of the pending application is claimed under 35 U.S.C. 119(e), 120, 121, or 365 in another application that has: (a) issued as a U.S. patent, or (b) published as a statutory invention registration, a U.S. patent application publication, or an international patent application publication in accordance with PCT Article 21(2), a member of the public may obtain a copy of: the file contents; the pending application as originally filed; or any document in the file of the pending application.
- (2) If the application is incorporated by reference or otherwise identified in a U.S. patent, a statutory invention registration, a U.S. patent application publication, or an international patent application publication in accordance with PCT Article 21(2), a member of the public may obtain a copy of the pending application as originally filed.

Signature

Kenneth Slater

Typed or printed name

Registration Number, if applicable

7034861150

Telephone Number

Date

11/7/08

FOR PTO USE ONLY

Approved by: SA

(initials)

Unit: _____

This collection of information is required by 37 CFR 1.11 and 1.14. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. BRING TO: File Information Unit, Room 2E04, 2900 Crystal Drive, Arlington, Virginia.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



US006713610B1

36

(12) **United States Patent**
Kucherlapati et al.(10) Patent No.: **US 6,713,610 B1**
(45) Date of Patent: **Mar. 30, 2004**(54) **HUMAN ANTIBODIES DERIVED FROM
IMMUNIZED XENOMICE**(76) Inventors: **Raju Kucherlapati**, 8 Gracie La.,
Darien, CT (US) 06820; **Aya**
Jakobovits, 2021 Monterey Ave.,
Menlo Park, CA (US) 94025; **Daniel G.**
Brenner, 86 Central Ave., Redwood
City, CA (US) 94601; **Daniel J. Capon**,
90 Woodridge Rd., Hillsborough, CA
(US) 94010; **Sue Klapholz**, 76 Peter
Coutts Cir., Stanford, CA (US) 94305(*) Notice: Subject to any disclaimer, the term of this
patent is extended or adjusted under 35
U.S.C. 154(b) by 52 days.(21) Appl. No.: **09/614,092**(22) Filed: **Jul. 11, 2000****Related U.S. Application Data**(60) Division of application No. 08/724,752, filed on Oct. 2,
1996, now Pat. No. 6,150,584, which is a continuation-in-
part of application No. 08/430,938, filed on Apr. 27, 1995,
now abandoned, and a continuation-in-part of application
No. 08/234,145, filed on Apr. 28, 1994, now abandoned, and
a continuation-in-part of application No. 08/112,848, filed
on Aug. 27, 1993, now abandoned, and a continuation-in-
part of application No. 08/031,801, filed on Mar. 15, 1993,
and a continuation-in-part of application No. 07/919,297,
filed on Jul. 24, 1992, now abandoned, and a continuation-
in-part of application No. 07/610,515, filed on Nov. 8, 1990,
now abandoned, and a continuation-in-part of application
No. 07/466,008, filed on Jan. 12, 1990, now abandoned.(51) Int. Cl.⁷ **A61K 39/395; C07K 16/00**(52) U.S. Cl. **530/388.23; 530/387.1;**
530/388.1; 530/388.15; 424/130.1; 424/132.1;
424/141.1; 424/147.1; 424/145.1(58) Field of Search **530/350, 387.1,**
530/388.1, 388.15, 388.23; 536/23.1; 435/320.1;
424/147.1, 145.1, 130.1, 141.1(56) **References Cited****U.S. PATENT DOCUMENTS**4,950,599 A 8/1990 Bertling 435/456
4,959,313 A 9/1990 Taketo 435/69.1
5,204,244 A 4/1993 Fell et al. 435/68
5,286,647 A 2/1994 Handley et al. 435/240.27
5,545,806 A 8/1996 Lonberg et al. 800/802
5,545,807 A 8/1996 Surani et al. 800/2
5,569,825 A 10/1996 Lonberg et al. 800/2**FOREIGN PATENT DOCUMENTS**EP 0 298 807 A1 1/1989
EP 0 315 062 B1 5/1989
EP 0 322 240 B1 6/1989
EP 0 459 372 A3 12/1991
EP 0 463 151 B1 1/1992
WO WO 90/04036 4/1990
WO WO 91/00906 1/1991
WO WO 91/10741 7/1991
WO WO 92/03918 3/1992
WO WO 92/22645 12/1992
WO WO 93/05165 3/1993WO WO 93/12227 6/1993
WO WO 94/00569 1/1994
WO WO 94/02602 2/1994
WO WO 94/25585 11/1994
WO WO 96/34096 10/1996**OTHER PUBLICATIONS**Li et. al.; The I Binding Specificity of Human ... and
Complementary Determining Region 3, 1996, J. Mol. Biol.
256:577-589.*Albertson, et al., "Construction and characterization of a
yeast artificial chromosome library containing seven human
genome equivalents," *Proc. Natl. Acad. Sci. U.S.A.*
87:4256-4260 (1990).Aldhous, "Transgenic mice display a class (switching) act,"
Science 262:1212-1213 (1993).Ayres, et al., "Sequence homology requirements for inter-
molecular recombination in mammalian cells," *Proc. Natl.*
Acad. Sci. U.S.A. 83:5199-5203 (1986).Berman, et al., "Content and organization of the human Ig
V_H locus: definition of three new V_H families and linkage to
the Ig C_H locus" *EMBO J.* 7:727-738 (1988).Blankenstein, et al., "Immunoglobulin V_H region genes of
the mouse are organized in overlapping clusters" *Eur. J.*
Immunol. 17:1351-1357 (1987).Brinster, et al., "Introns increase transcriptional efficiency in
transgenic mice," *Proc. Natl. Acad. Sci. U.S.A.* 85:836-840
(1988).Brownstein, et al., "Isolation of single-copy human genes
from a library of yeast artificial chromosomes," *Science*
244:1348-1351 (1989).Bruggemann, et al., "A repertoire of monoclonal antibodies
with human heavy chains from transgenic mice," *Proc. Natl.*
Acad. Sci. U.S.A. 86:6709-6713 (1989).Bruggemann, et al., "Construction, function and immuno-
genicity of recombinant monoclonal antibodies," *Behring*
Inst. Mitt. 87:21-24 (1990).Bruggemann, et al., "Human antibody production in trans-
genic mice: expression from 100 kb of the human IgH
locus," *Eur. J. Immunol.* 21:1323-1326 (1991).Bruggemann, et al., "Strategies for expressing human anti-
body repertoires in transgenic mice," *Immunology Today*
17:391-397 (1996).Burke, et al., "Cloning of large segments of exogenous DNA
into yeast by means of artificial chromosome vectors,"
Science 236:806-812 (1987).Buttin, et al., "Exogenous Ig rearrangement in transgenic
mice: a new strategy for human monoclonal antibody pro-
duction," *Trends in Genetics* 3(8):205-206 (1987).

(List continued on next page.)

Primary Examiner—Anne M. Wehbe'

(57) **ABSTRACT**Fully human antibodies against a specific antigen can be
prepared by administering the antigen to a transgenic animal
which has been modified to produce such antibodies in
response to antigenic challenge, but whose endogenous
have been disabled. Various subsequent manipulations can
be performed to obtain either antibodies per se or analogs
thereof.**14 Claims, 18 Drawing Sheets**